Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of RGEN's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Aug 14, 2025
Questions asked 11 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 11 numbered comments
  3. 3. Company replies 7 CORRESP
  4. 4. Reviews closed 4 of 4 closing letter

Half the closed reviews took 64 days or less from the first letter to the closing letter.

Form 10-K

2025-08-14 to 2025-09-10 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2025-09-10
Goodwill and impairmentAcquisitions
Note 5 - Acquisitions · 2024 Acquisitions, page 88
SEC asked
You have identified developed technology and goodwill from the Tantti acquisition totaling $76 million. On page 14, you refer to patent assets acquired as part of this acquisition and your policy footnote on page 83 refers to the estimated fair value of customer relationships, developed technologies, trademark/tradename, patents, noncompete agreements and in-process research and development from your acquisitions.
Rest of the question

Given the significance of the allocation to goodwill and developed technology, please tell us why you have not identified or assigned value to patents or other intangible assets from this acquisition. Refer to ASC 805-20-55. As part of your response, please include a general description of the procedures you follow to identify intangible assets in your business acquisitions.

RGEN answered
The Company respectfully advises the Staff that as disclosed in the Form 10-K, the Company’s growth strategy includes making targeted acquisitions of businesses that have innovative technologies and products. While conducting due diligence on the target’s business and following completion of a business acquisition, the Company conducts a thorough review of both financial and operating information of the acquiree, including but not limited to historical financial statements, product and customer sales data, significant executory contracts, financial and tax diligence reports, tax returns,
Rest of the answer

marketing materials, and website information. This information is supplemented through discussions with key members of management of the acquiree.

This information is then analyzed by Company management including members of the finance, legal, and operations departments as well as executive leadership, and where necessary, third party valuation professionals and third party accounting professionals, to identify assets that lack physical substance and meet either the separability criterion or contractual-legal criterion described in ASC 805-20-55-2 through 55-5.

After applying the separability criterion and the contractual-legal criterion to identify intangible assets, the Company considers the combination of individual intangible assets for purposes of grouping complimentary intangible assets if the assets have similar useful lives and pattern of consumption of economic benefits, consistent with the guidance in ASC 805-20-55-18. The Company also considers other information in making the unit of account determination, including the list of factors described in ASC 350-30-35. The Company also considers materiality in making this assessment.

Material intangible assets recognized in the Company’s acquisitions can be primarily characterized as customer-related and technology-based intangible assets. In certain acquisitions, the Company has identified and recognized contract-based intangible assets based on the Company’s evaluation of contractual terms relative to market terms. Marketing-related intangible assets, including trademark, tradename and noncomplete agreements are not generally material based on the relative size of the acquirees’ operations and also considering the Company’s plan to continue or integrate brand-related assets into Repligen’s product portfolio. Artistic-related intangible assets are not typically present in the bioprocessing market.

The Company followed its customary procedures described above to determine the identifiable intangible assets in the acquisition of Tantti. At the time of announcing the definitive agreement to acquire Tantti on July 29, 2024, Tantti had planned to launch its first generation chromatography bead product in the second half of 2024. Tantti’s first generation chromatography bead product commercially launched on December 9, 2024, one week after Repligen’s completion of the acquisition. In connection with the Company’s acquisition of Tantti, the following material identifiable intangible assets were recognized for accounting purposes:

Developed technology: As disclosed in Note 5 in the Form 10-K, the Company recognized a developed technology intangible asset representing a combined unit of account of all intellectual property (inclusive of patented and unpatented technologies), know-how, business processes, and technological processes underlying Tantti’s portfolio of microporous chromatography beads. The Company acknowledges that certain individual elements or attributes of the combined developed technology asset might meet the contractual-legal criterion (e.g., patents) or separability criterion, however these individual elements or attributes are highly interrelated with the other individual elements or attributes of the combined developed technology asset. Management considered the guidance in ASC 350-30-35-23 through 35-24 and 805-20-55-18 in making this determination, noting that the combined developed technology asset, and not the individual elements or attributes, represents the highest and best use of the developed technology assets and the period of economic benefit of the individual elements or attributes is similar. The generation of cash flows for Tantti is driven by the combined unit of account, which is disclosed as

“Developed Technology”.

Based on its customary procedures described above to determine the identifiable intangible assets in the acquisition of Tantti, the Company determined the following types of intangible assets were either not material to the consolidated financial statements and therefore not recognized, or did not meet either the separability criterion or contractual-legal criterion under ASC 805-20-55-2 through 55-5:

Read in the reply
In its next report

First report after the company's reply of Aug 26, 2025: 10-Q filed Nov 4, 2025 ↗, against the 10-Q filed Aug 7, 2025 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2025-09-10

Form 10-K for the fiscal year ended December 31, 2023

2024-07-24 to 2024-08-12 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2024-08-12
Legal and contingenciesDerivatives and hedging
Notes to the Financial Statements
SEC asked
Convertible Senior Notes, page 114 1. We note that your Convertible Notes are convertible at the option of the holder and that the make-whole fundamental change provision may trigger an increase in the conversion rate. Please explain to us how you evaluated the Notes to determine whether each conversion feature was required to be bifurcated and accounted for as a derivative under ASC 815.
Rest of the question

In your response, please specifically address whether each conversion option contingency meets the definition of a derivative and, if so, whether it qualifies for the scope exception for contracts involving an entity's own equity as set forth in ASC 81510-15-74(a). Specifically address the steps in ASC 815-40-15-7A through 15-7H, the conditions beginning in ASC 815-40-25-7, and if the make-whole provision violates the condition in ASC 815-40-25-39. Please also revise your accounting policy disclosure accordingly in your future filings.

RGEN answered
, please specifically address whether each conversion option contingency meets the definition of a derivative and, if so, whether it qualifies for the scope exception for contracts involving an entity’s own equity as set forth in ASC 81510-15-74(a). Specifically address the steps in ASC 815-40-15-7A through

15-7H, the conditions beginning in ASC 815-40-25-7, and if the make-whole provision violates the condition in ASC 815-40-25-39.
Rest of the answer

Please also revise your accounting policy disclosure accordingly in your future filings.

Page

RESPONSE:

The Company notes that while the discussion below is focused on the 2023 Notes, the same analysis is applicable to the 2019 Notes which have equivalent terms.

The Company assessed the embedded conversion feature to determine if bifurcation from the 2023 Notes and derivative accounting pursuant to ASC 815-15-25-1 is required. As part of the analysis, the embedded conversion feature was assessed to determine if it meets the definition of a derivative and qualifies for a derivative scope exception. This analysis included evaluating all contingent exercise provisions and settlement provisions of the 2023 Notes.

The 2023 Notes may be converted in multiple different situations related to (i) trading price of the 2023 Notes, (ii) the Company’s issuance of certain securities or rights, (iii) upon the occurrence of defined corporate events (which includes a make-whole fundamental change), (iv) common stock price target trigger, (v) in connection with the Company’s redemption option, and (vi) non-contingently after the free convertibility period. Because of the commonality of the underlying (i.e., settlement price is always based on the value of equity) irrespective of the triggering events

(and corresponding settlement provisions), the Company determined the conversion feature represents a single option with multiple exercise triggers. Thus, the conversion feature represents a single unit of analysis for accounting purposes.

Additionally, if a holder converts upon a make-whole fundamental change (representing one of the defined corporate event exercise triggers described above) or in connection with the Company’s redemption option, the holder may be eligible to receive a make-whole premium through an increase to the conversion rate. The make-whole premium was designed to compensate the holder for lost

“time-value” of the conversion option (i.e., the difference between the conversion option’s fair value and intrinsic value) by using a standard option pricing tool. There were no inputs to the construction of the make-whole table other than standard, permitted option pricing inputs.

As discussed in further detail, the Company respectfully advises that the conversion feature meets the scope exception to the derivative accounting guidance in ASC 815-10-15-74(a) and does not meet the bifurcation criteria in

ASC 815-15-25-1(c). Therefore, the Company concluded that the conversion feature should not be accounted for as a derivative.

Accounting Analysis – 2023 Notes

The

Company first concluded the conversion feature meets the definition of a derivative instrument consistent with ASC 815-10-15-83, as the feature has an underlying, notional or payment provision, no initial net investment and provide for net settlement.

Under the scope exception pursuant to ASC 815-10-15-74(a), a reporting entity is not required to treat a contract issued or held by that reporting entity as a derivative instrument if the contract is both (1) indexed to its own stock and (2) classified in stockholders’ equity in its statement of financial position. If the conversion feature qualifies for this derivative scope exception, bifurcation and separate derivative accounting is not required. Both criteria are evaluated below:

(1). Indexed to reporting entity’s common stock – ASC 815-40-15-7 requires that companies apply a two-step approach in evaluating whether an equity-linked financial instrument or embedded feature is indexed to its own stock. The first step requires an evaluation of the instrument’s contingent exercise provisions, if any. The second step requires an evaluation of the instrument’s settlement provisions.

Step 1: ASC 815-40-15-7(a) — Evaluate the instrument’s contingent exercise provisions, if any.

Under

ASC 815-40-15-7A, an exercise contingency does not preclude an instrument (or embedded feature) from being considered indexed to an entity’s own stock if it is not based on either (a) an observable market, other than the market for the issuer’s stock (if applicable) or (b) an observable index, other than an index calculated or measured solely by reference to the issuer’s own operations.

The conversion feature contains standard contingent exercise provisions, which include (i) trading price of the

2023 Notes, (ii) the Company’s issuance of certain securities or rights, (iii) upon the occurrence of defined corporate events (which includes a make-whole fundamental change), (iv) common stock price target trigger (v) in connection with the Company’s redemption option, and (vi) non-contingently after the free convertibility period. The contingent exercise provisions of the 2023 Notes are not based on an observable market or index that is not based on the

Company’s operations, and thus do not preclude the conversion feature from being indexed to the Company’s own stock. Step 2 of the indexation guidance was next considered.

Step 2: ASC 815-40-15-7(b)

— Evaluate the instrument’s settlement provisions.

The second step is evaluating whether the settlement provisions are consistent with a fixed-for-fixed equity instrument (fixed conversion price). This includes evaluating the increase in the settlement provisions of the 2023 Notes under a make-whole fundamental transaction. The 2023 Notes have the following settlement provisions whereby the conversion rate may be adjusted:

•

Anti-dilution adjustment provisions to the conversion rate;

Voluntary increase in the conversion rate; and

Conversion rate adjustment upon occurrence of (i) a make-whole fundamental change or (ii) holder conversion in relation to the exercise of the Company redemption option.

The settlement provisions were evaluated under ASC 815-40-15-7C through 15-7H, as summarized below:

Anti-dilution provision. The 2023 Notes include a standard anti-dilution provision that protects the holder’s exposure to the risks arising from certain events such as a stock split or a dividend. ASC 815-40-15-7E provides that adjustments to the conversion price as a result of commercially reasonable anti-dilution provisions and other corporate events would not preclude the instrument from being indexed to an entity’s own stock. The 2023 Notes include standard anti-dilution provisions that adjusts the conversion price to offset the impact of the events noted above. Each of these adjustments are consistent with the guidance for equity accounting illustrated by Example 17 of ASC

815-40-55. As such, the anti-dilution provision meets the criterion in ASC 815-40-15-7E and does not preclude the conversion feature from being considered indexed to the Company’s own stock.

Voluntary increase in the conversion rate. The 2023 Notes include a provision whereby the Company may voluntarily increase the conversion rate at the discretion of the Company’s Board of Directors. ASC 815-40-15-7H provides that if an equity-linked financial instrument includes terms that allow the issuer to modify the instrument at any time provided such modifications benefit the counterparty, then these terms do not preclude the instrument from being considered indexed to the entity’s own stock. The increase in the conversion rate benefits the 2023 Notes holder (i.e., counterparty) thus, the Company concluded that such provision does not preclude the conversion feature from being considered indexed to an entity’s own stock.

Make-whole fundamental change premium. The 2023 Notes include a make-whole provision that adjusts the conversion rate upon the occurrence of a fundamental change or upon the exercise of the Company redemption option whereby the holder may be eligible to receive a make-whole premium through an increase to the conversion rate. The Company evaluated the make-whole provision under ASC 815-40-15-7C through 15-8 to determine whether the equity-linked feature can be considered indexed to the Company’s own stock. Under ASC 815-40-15-7D, the make-whole feature would still be considered indexed to the Company’s own stock if the only variables that could affect the settlement amount would be inputs to the fair value of a fixed-for-fixed forward or option on equity shares. Under ASC

815-40-15-7F, the make-whole feature would not be considered indexed to the Company’s own stock if its settlement amount is affected by variables that are extraneous to the pricing of a fixed-for-fixed option or forward contract on equity shares.

The make-whole provision in the 2023 Notes adjusts the conversion rate to compensate the holders of the notes for lost time value as a result of an early settlement. The number of additional shares is determined based on a table with axes of stock price and time, which would both be inputs in a fair value measurement for a fixed-for-fixed option on equity shares. The make-whole table was designed such that the aggregate fair value of the consideration deliverable (including the cash paid for principal and, at the Company’s option, cash or shares delivered for the conversion premium, that is, the fair value of the underlying shares per bond plus the make-whole shares) would be expected to approximate the fair value of the convertible debt instrument at the settlement date, subject to market changes in relevant option pricing inputs, assuming no change in relevant pricing inputs (other than stock price and time) since the instrument’s inception. The make-whole provision adjustment within the 2023 Notes is consistent with Example 19 in ASC 815-40-55-45 through 46 wherein it is concluded that the adjustment to the settlement amount due to the make-whole adjustment does not preclude the conversion option from being deemed indexed to the Company’s own stock. As a result, the provision for adjustments based on this make-whole table does not preclude the conversion feature from being considered indexed to the Company’s own stock.

As the only variables that could affect the settlement amount would be inputs to the fair value of a fixed-for-fixed forward or option on equity shares, the settlement adjustments, including the make-whole feature, included in the 2023 Notes do not preclude the conversion feature from being considered indexed to the Company’s own stock under ASC

815-40-15-7D.

(2).

Classified in stockholders’ equity in its statement of financial position – The Company highlights that the principal (and accrued interest) balance of the 2023 Notes is only settled in cash, and the Company has the option to settle the conversion feature in cash, common stock shares or a combination of the two (e.g., “Instrument C’’, as defined within EITF Issue 90-19.). ASC 815-40-25 states that to determine whether the embedded conversion feature would be classified in stockholders’ equity, the reporting entity must consider who controls the settlement and whether the settlement will be in shares or cash. ASC 815-40-25-2 states that if the contract provides the entity with the choice of net cash settlement or settlement in shares, the settlement in shares is assumed and contracts that require settlement in shares are equity instruments.

condition in ASC 815-40-25-39 states that guidance in ASC 815-40-25-7 through 25-30 would not apply if the holder may only realize the value of the conversion option by exercising the option and receiving the entire proceeds in a fixed number of shares or the equivalent amount of cash (at the discretion of the issuer). The 2023 Notes do not meet this exception because the principal portion of the 2023 Notes is settled in cash and the make-whole provision is designed so that the holder of such notes would receive the approximate fair value of the notes at the settlement date and the Company has the option to settle the conversion option in cash, shares or a combination of the two. Therefore, the Company assessed the additional provisions beginning in ASC 815-40-25-7 through 25-35 and determined that all of the criteria have been met and, as such, the conversion option should be classified in stockholders’ equity under ASC 815-40-25. The

Company’s analysis is outlined below with respect to key conditions of ASC 815-40-25:

There is no explicit requirement to settle the contract in cash;

The Company has sufficient authorized and unissued shares;

The 2023 Notes contain an explicit share limit;

There is no requirement to cash settle the contract if the Company fails to make timely filings with the SEC; and

There is no cash-settled top-off or make whole provision as described in

ASC 815-40-25-30.

As the conversion feature is also deemed indexed to the Company’s own stock, the scope exception available under ASC 815-10-15-74 is met and bifurcation from the 2023 Notes is not required.

Accounting Analysis – 2019 Notes

The Company completed a similar accounting analysis with respect to convertible notes issued on July 15, 2019 (“2019 Notes”), The Company assessed the embedded conversion feature to determine if bifurcation from the 2019 Notes and derivative accounting pursuant to ASC 815-15-25-1 is required. As part of the analysis, the embedded conversion feature was assessed to determine if it meets the definition of a derivative and qualifies for a derivative scope exception.

The conversion feature and settlement provisions of the 2019 Notes are similar to those contained in the 2023 Notes. The 2019 Notes may be converted in multiple different situations related to (i) trading price of the 2019 Notes, (ii) the Company’s issuance of certain securities or rights, (iii) upon the occurrence of defined corporate events (which includes a make-whole fundamental change), (iv) common stock price target trigger, (v) in connection with the Company’s redemption option, and (vi) non-contingently after the free convertibility period. The settlement provisions of the 2019 Notes include anti-dilution adjustment provisions to the conversion rate, voluntary increase in the conversion rate and conversion rate adjustment upon occurrence of (i) a make-whole fundamental change or (ii) holder conversion in relation to the exercise of the Company redemption option.

Because the conversion feature and settlement provisions of the 2019 Notes are similar to those contained in the 2023 Notes, the analysis and overall accounting conclusion for the 2019 Notes is the same as the 2023 Notes. The Company respectfully advises that the conversion feature meets the scope exception to the derivative accounting guidance in ASC 815-10-15-74(a) and does not meet the bifurcation criteria in ASC

815-15-25-1(c). Therefore, the Company concluded that the 2019 Notes’ conversion feature should not be accounted for as a derivative.

The company fully settled all outstanding 2019 Notes as of July 17, 2024.

Revised Accounting Policy Disclosure in Future Filings

In our future filings, beginning with our Form 10-Q for the quarter ending September 30, 2024, we will include the following accounting policy disclosure in the “Summary of Significant Accounting Policies” footnote:

Convertible Instruments

The Company evaluates the embedded conversion feature within its convertible debt instruments under ASC

815-15 and ASC 815-40 to determine if the conversion feature meets the definition of a derivative and, if so, whether to bifurcate the conversion feature and account for it as a separate derivative liability. Based on our analysis, our convertible notes do not have an embedded conversion feature requiring bifurcation under ASC 815-15 and thus are accounted for as a single unit of account, a liability under ASC 470.

***

If you should have any questions or comments with respect to the foregoing, please contact me at 617-570-1762 or via e-mail at [email protected].

Read in the reply

Also in this review: closing letter, 2024-08-12

Form 10-K for the fiscal year ended December 31, 2015

2016-12-22 to 2017-03-08 · 1 question · 1 letter from the SEC, 3 from the company
Review closed 2017-03-08
RevenueSegments
Financial Statements · Segment Reporting, page 65
SEC asked
Please provide us, for the fiscal years 2015 and 2014 and for the nine months ended September 30, 2016, product revenues for:  Protein A ligands;  OPUS® pre-packed chromatography column line;  Protein A chromatography resins;  LONG®R3 IGF-1; and  ATF System as discussed under “Our Products” on page 3. Also, tell us your consideration for providing product revenue disclosures pursuant to ASC 280-10-50-40.
RGEN answered
Repligen Corporation (the “Company”) hereby advises the staff (the “Staff”) of the Securities and

Exchange Commission (the “Commission”) that the Company has received the Staff’s letter dated December 22, 2016 (the “Comment Letter”), regarding the Commission’s review of the Company’s Annual

Report on Form 10-K for the fiscal year ended December 31, 2015.
Rest of the answer

The Comment Letter requests that the Company respond within ten (10) business days from the date thereof, or inform the Staff of when the Company would provide a response.

The Company respectfully requests an extension of an additional ten (10) business days until January 24, 2017 to respond to the Comment Letter in order to provide sufficient time for the Company to prepare the necessary response. The

Company is committed to responding to the Comment Letter promptly and intends to provide a response to the Staff no later than January 24, 2017. Should you have any questions regarding the request made herein, please do not hesitate to contact me at (781) 419-1862. Thank you very much for your courtesy and cooperation in this matter.

Read in the reply
In its next report

First report after the company's reply of Jan 9, 2017: 10-K filed Feb 23, 2017 ↗, against the 10-K filed Feb 25, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: company letter, Jan 24, 2017, company letter, Feb 14, 2017, closing letter, 2017-03-08

Form 10-K for the year ended December 31, 2013

2014-12-23 to 2015-02-25 · 8 questions · 2 letters from the SEC, 2 from the company
Review closed 2015-02-25
Revenue
Our Products for the Manufacturing of Biologic Drugs, page 2
SEC asked (1)
We note that your Strategic Supplier Alliance Agreement with GE Healthcare appears to be a material agreement as it has been filed as an exhibit pursuant to Item 601(b)(10) of Regulation S-K. Please expand your disclosure regarding the agreement to provide the material terms, including the parties’ rights and obligations, the duration of the agreement, termination provisions, and any payment provisions.
RGEN answered
The Company acknowledges the Staff’s comment. In future filings, the Company will expand its disclosure regarding the HDAC Agreement with

BioMarin substantially as set forth below in italicized and underlined text.

HDAC Agreement with BioMarin

On January 21, 2014, we out-licensed our HDACi portfolio, which includes the Friedreich’s ataxia program, to BioMarin

Pharmaceuticals Inc. Friedreich’s ataxia is an inherited disease that causes progressive damage to the nervous system resulting in symptoms ranging from impaired walking and speech problems to heart disease.
Rest of the answer

Pursuant to the terms of the agreement, BioMarin agrees to use commercially reasonable efforts to commercialize HDACi portfolio product until the later of (i) the expiration of the last-to-expire valid claim of an issued and unexpired patent or pending patent application claiming a compound included in the agreement or (ii) 10 years. Under the terms of the agreement, Repligen received an upfront payment of $2 million in January 2014 from BioMarin and we have the potential to receive up to $160 million in future milestone payments for BioMarin’s development, regulatory approval and commercial sale of portfolio compounds included in the agreement. These potential milestone payments are approximately 37% related to clinical development and 63% related to initial commercial sales in specific geographies. In addition, Repligen is eligible to receive royalties on sales of qualified products developed. The royalty rates are tiered and begin in the mid-single-digits for the first HDACi portfolio product and for the first non-HDACi portfolio product with lesser amounts for any backup products developed under the agreement. Repligen’s receipt of these royalties is subject to customary offsets and deductions. There are no refund provisions in this agreement. Royalties under this agreement are paid on a country-by-country basis during the period beginning on the first commercial sale of a compound in such country, until the later of: (i) the expiration of exclusivity period granted by a governmental authority to prevent the entry of generic product into such country; (ii) the expiration of the last-to-expire valid claim of an issued and unexpired patent or pending patent application claiming such compound in such country; or (iii) ten years following the first commercial sale of such HDACi portfolio product in any country. Royalty payments on products derived from the compounds included in the agreement are calculated by multiplying net sales of such product for the calendar year by an applicable royalty rate based on incremental net sale amounts.

Read in the reply
In its next report

First report after the company's reply of Feb 19, 2015: 10-K filed Mar 17, 2015 ↗, against the 10-K filed Mar 14, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Research and Development, page 4
SEC asked (2)
Please expand your disclosure for your HDAC Agreement with BioMarin to describe the material terms of the agreement, including the parties’ rights and obligations, the duration of the agreement, termination provisions and royalty rates. Also, please file the agreement as an exhibit pursuant to Item 601(b)(10) of Regulation S-K.
RGEN answered
The Company acknowledges the Staff’s comment and respectfully directs the Staff’s attention to the Company’s Current Report on

Form 8-K, filed on January 30, 2015, in which the Company discloses that, on January 26, 2015, the Company received from Pfizer a notice of termination for convenience under the SMA Agreement.
Rest of the answer

In light of the termination of the SMA

Agreement, in future filings, the Company will modify its disclosure regarding the SMA Agreement with Pfizer substantially as set forth below in italicized and underlined text.

SMA Agreement with Pfizer

On

December 28, 2012, we entered into an exclusive worldwide licensing agreement (the “License Agreement”) with Pfizer to advance the SMA program, which is led by RG3039 and also includes backup compounds and enabling technologies. Under the terms of the License Agreement, we received $5 million from Pfizer as an upfront payment on January 22, 2013 and a $1 million milestone payment on September 4, 2013. Pursuant to this License Agreement, Pfizer assumed full responsibility for the SMA program, including the conduct of the clinical trials necessary for any product approvals. On January 26, 2015, Pfizer issued to us a notice of its termination of the License Agreement for convenience, effective as of April 26, 2015.

Read in the reply
In its next report

First report after the company's reply of Feb 19, 2015: 10-K filed Mar 17, 2015 ↗, against the 10-K filed Mar 14, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Research and Development, page 4
SEC asked (3)
Please expand your disclosure for your SMA Agreement with Pfizer to describe the termination provisions of the agreement. With regard to the duration of the agreement, we note that the royalty term of the agreement is based on the later of (a) expiration of the licensed patents or (b) a predetermined time after the first commercial sale of the first product in a country.
Rest of the question

Please revise the duration disclosure to provide the expiration date of the last to expire patent and the “predetermined time” referenced in your disclosure.

RGEN answered
The Company acknowledges the Staff’s comment. In future filings, the Company will expand its disclosure regarding its HDAC patent applications substantially as set forth below in italicized and underlined text:

On January 21, 2014, the Company out-licensed its HDAC Inhibitor (HDACi) portfolio to BioMarin Pharmaceuticals Inc. The Company’s outlicensed HDACi portfolio included patent applications in the United States as well as patent applications in the EU, Canada, Japan and

Australia.
Rest of the answer

Patents, if any, that are granted based on these patent applications are expected to expire from 2029 to 2032.

* * *

On behalf of the Company, I hereby acknowledge that:

• the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Feb 19, 2015: 10-K filed Mar 17, 2015 ↗, against the 10-K filed Mar 14, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Significant Customers and Geographic Reporting, page 5
SEC asked (4)
Please revise your disclosure in this section to identify the customer which accounted for 35% of your revenues for the fiscal year ended December 31, 2013. Also, please identify customers A, B and C in the section entitled “Concentrations of Credit Risk and Significant Customers” on page 67.
RGEN answered

No numbered answer found in the reply. Read the reply ↗

In its next report

First report after the company's reply of Feb 19, 2015: 10-K filed Mar 17, 2015 ↗, against the 10-K filed Mar 14, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Patent, Licenses and Proprietary Rights, page 6
SEC asked (5)
Please expand your disclosure for your material patents and patent applications to include the following information:  the type of patent protection such as composition of matter, use or process for your U.S. Patent No. 7,691,608 B2;  the jurisdiction where your OPUS pre-packed column patent application is pending and the expected expiration date if the patent is issued;  the expiration dates of U.S. Patent Nos.
Rest of the question

7,888,366 and 7,985,755; and  the jurisdiction where your histone deacetylase inhibitors patent application is pending and the expected expiration date if the patent is issued.

RGEN answered

No numbered answer found in the reply. Read the reply ↗

In its next report

First report after the company's reply of Feb 19, 2015: 10-K filed Mar 17, 2015 ↗, against the 10-K filed Mar 14, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

SEC letter of Feb 13, 2015 ↗ no reply letter on EDGAR
Research and Development, page 4
SEC asked (1)
We note your response to our prior comment 2. Notwithstanding your confidential treatment request for provisions and terms in the HDAC Agreement with BioMarin, we deem information regarding the parties’ rights and obligations, duration of the agreement and termination provisions to be material to investors.
Rest of the question

Accordingly, please expand your proposed disclosure to be included in future filing to provide the parties rights and obligations, duration of the agreement and termination provisions.

RGEN answered

No reply letter found.

In its next report

First report after the SEC's letter of Feb 13, 2015: 10-K filed Mar 17, 2015 ↗, against the 10-K filed Mar 14, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Research and Development, page 4
SEC asked (2)
We note your response to our prior comment 3. Notwithstanding your confidential treatment request for cessation provisions of royalties, we deem information relating to the duration of the agreement to be material to investors.
Rest of the question

Accordingly, please expand your proposed disclosure to be included in future filings to provide the expiration date of the last to expire patent and the “predetermined time” referenced in your disclosure on which the payment of royalties is based.

RGEN answered

No reply letter found.

In its next report

First report after the SEC's letter of Feb 13, 2015: 10-K filed Mar 17, 2015 ↗, against the 10-K filed Mar 14, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Patent, License and Proprietary Rights, page 6
SEC asked (3)
We note your response to our prior comment 5. Please expand your proposed disclosure to provide the expected expiration date if your HDAC inhibitors patent application is granted.
RGEN answered

No reply letter found.

In its next report

First report after the SEC's letter of Feb 13, 2015: 10-K filed Mar 17, 2015 ↗, against the 10-K filed Mar 14, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Dec 30, 2014, company letter, Jan 20, 2015, closing letter, 2015-02-25

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 17 letters filed since 2014-12-23. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.